The arrival of a 750mcg PTH injection in Australia has been relatively limited , with distribution primarily via specialist endocrinologists and designated hospitals . Initial distribution numbers for this increased strength remain unavailable from the company, although experts suggest gradual adoption penetration. Patient access is managed by the